Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | DRD3 | P35462 | 7/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL550220 | 0.98 | DRD2 (0.44) | DRD2DRD3PNMTMAPK1 | |
| SCHEMBL1019988 | 0.85 | — | — | |
| SCHEMBL397802 | 0.85 | — | — | |
| SCHEMBL9500822 | 0.85 | PNMT (0.41) | DRD2DRD3PNMTMAPK1HTR2C | |
| Hydrochloric Acid SCHEMBL12485568 | 0.83 | DRD2 (0.40) | DRD2DRD3PNMTMAPK1 | |
| Hydrochloric Acid SCHEMBL22395725 | 0.83 | DRD2 (0.40) | DRD2DRD3PNMTMAPK1 | |
| Hydrochloric Acid SCHEMBL16054017 | 0.83 | PNMT (0.44) | DRD2DRD3PNMTMAPK1HTR2C | |
| SCHEMBL3725694 | 0.80 | DRD2 (0.38) | DRD2DRD3PNMTMAPK1HTR2C | |
| SCHEMBL8352318 | 0.79 | — | — | |
| Urea SCHEMBL21906543 | 0.76 | PNMT (0.40) | DRD2DRD3PNMTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0347766-B1 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | THOMAE GMBH DR K (DE) | 1994-05-25 | — | — | EP | claimed |
| EP-0555824-A1 | N-alpha-arylsulfonylated benzimidazolylalaninamide derivatives, medicaments based thereon and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-18 | — | — | EP | claimed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | claimed |
| JP-2045489-A | — | — | None | — | — | JP | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-11267825-B2 | Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-03-08 | — | — | US | disclosed |
| US-20200354379-A1 | NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-12 | — | — | US | disclosed |
| US-10774078-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2020-09-15 | — | — | US | disclosed |
| EP-3704127-A1 | NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2020-09-09 | — | — | EP | disclosed |
| US-20190330202-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10392380-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0347766-A3 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1991-07-10 | — | — | EP | disclosed |
| EP-0347766-A3 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1991-07-10 | — | — | EP | disclosed |
| JP-H0245489-A | NEW 4,5,7,8-TETRAHYDRO-6H-THIAZOLO(5,4-D)AZEPINES AND DRUG COMPOSITION CONTAINING THE COMPOUNDS | DR KARL THOMAE GMBH | 1990-02-15 | — | — | JP | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774078-B2 | Compounds | UCHL1, UCHL3, UCHL5 | DRD2 3085/4885DRD3 2644/4885PNMT 3651/4885 |
| US-10392380-B2 | Compounds | UCHL1, UCHL3, UCHL5 | DRD2 3085/4885DRD3 2644/4885PNMT 3651/4885 |
| US-20190330202-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | DRD2 3354/4885DRD3 2791/4885PNMT 4019/4885 |
| US-20200354379-A1 | NOVEL, HIGHLY ACTIVE AMINO-THIAZOLE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, BRD4 | DRD2 4223/4885DRD3 4358/4885PNMT 1671/4885 |
| US-11267825-B2 | Highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | HCCS, BRD4, IDO2 | DRD2 4367/4885DRD3 4469/4885PNMT 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.